MAZ51 is primarily used in research settings as a selective inhibitor of c-Kit and PDGFR (platelet-derived growth factor receptor) tyrosine kinases. It is commonly applied in studies involving cell signaling pathways related to cell proliferation, survival, and differentiation, particularly in cancer research. Scientists use MAZ51 to investigate the role of receptor tyrosine kinases in tumor development and metastasis, especially in cancers such as melanoma and leukemia where c-Kit signaling is dysregulated. Additionally, MAZ51 has been employed in studies exploring the molecular mechanisms of apoptosis and autophagy, helping to identify potential therapeutic targets. Its application is limited to in vitro and preclinical models due to lack of clinical approval.